The AI Pharma Surge Is Genuine — Cancer Could Soon Become Chronic Instead of Fatal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2025
0mins
Source: Benzinga
Pharma Sector Growth: Pharma stocks are experiencing a significant rally, with the Tema Oncology ETF up 45% year-to-date, driven by structural changes in the sector and increasing demand for innovative treatments, particularly in oncology.
Regulatory Clarity and M&A Activity: The regulatory environment is improving, leading to a surge in mergers and acquisitions within the healthcare sector, as companies seek to adapt to rising healthcare demands and replace revenue from expiring patents.
AI's Role in Drug Discovery: Artificial intelligence is enhancing the efficiency of drug discovery processes, making them cheaper and faster, although it has not yet taken over the discovery of new molecules.
Future of Cancer Treatment: Innovations such as gene editing and potential cancer vaccines could transform cancer from a deadly disease into a manageable chronic condition, with companies like Merck and Moderna leading the charge in this area.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 49.640
Low
17.00
Averages
32.47
High
63.00
Current: 49.640
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna's Strategic Return and Future Outlook
- Manufacturing Capacity Gap: CEO Stéphane Bancel warns that continental Europe currently lacks mRNA manufacturing capacity, particularly after BioNTech's announcement to close its German facilities, emphasizing the importance of collaborating with the EU to establish local production to address potential pandemic risks.
- Product Line Diversification: Moderna is expanding its mRNA platform technology into cancer treatment, recently announcing a new therapy for Lynch syndrome aimed at enhancing cancer prevention in patients, while hoping this new product will boost the company's market performance.
- Sales Growth Outlook: Despite expectations of a significant drop in sales post-COVID-19, Bancel states that Moderna is set to return to a growth trajectory this year, with four infectious disease vaccines already approved by European regulators and more products in phase three trials expected to drive revenue recovery.
- Infrastructure Enhancement: With manufacturing facilities in the US, Canada, the UK, and Australia, Bancel asserts that these infrastructures will enable Moderna to respond more rapidly to future pandemics, significantly enhancing global preparedness.
See More
Moderna Shares Surpass Analyst Target Price of $46.62
- Stock Performance: Moderna Inc (Ticker: MRNA) recently traded at $49.70, surpassing the average analyst 12-month target price of $46.62, indicating strong market confidence in the company's future, potentially attracting more investor interest.
- Analyst Reactions: When a stock reaches its target price, analysts typically either downgrade their valuation or raise their target price; the current market response to Moderna may prompt analysts to reassess their targets to reflect improvements in the company's fundamentals.
- Target Price Distribution: Among the 21 analysts covered by Zacks, target prices range from $21.00 to $135.00, with a standard deviation of $22.579, highlighting varying market perspectives on Moderna's future performance, necessitating careful risk and opportunity assessment by investors.
- Investor Decision-Making: With MRNA's stock price exceeding the target price, investors are presented with a timely opportunity to reassess whether the current price is merely a short-term fluctuation or a precursor to even higher target prices, thus deciding whether to hold or reduce their positions.
See More
Parabilis Pharmaceuticals IPO Raises $670 Million, Stock Surges 58%
- Biotech Boom: In 2023, the biotech sector is thriving, with Parabilis Pharmaceuticals raising $670 million in its IPO, surpassing Moderna's previous record of $604 million, indicating strong investor interest in innovative cancer treatments.
- Stock Performance: Parabilis's stock surged 58% on its first trading day, closing above $31, reflecting positive market sentiment towards its unique drug development platform, potentially laying the groundwork for future commercialization.
- Rapid R&D Progress: The company's lead candidate, zolucatetide, is set to enter a phase 3 clinical trial for non-cancerous tumors in the first half of next year, with over 150 patients studied so far, showing promising initial data that could transform existing treatment options.
- Financial Challenges: Despite the successful IPO, Parabilis reported a loss of $145 million last year, with R&D expenses reaching $125 million, highlighting ongoing financial pressures that increase investment risks, particularly against the backdrop of high R&D costs in the biotech sector.
See More
Parabilis IPO Sets Record, Promising Biotech Prospects Ahead
- Record Fundraising: Parabilis raised $670 million in its IPO, surpassing Moderna's previous record of $604 million, indicating strong market interest and heightened investor confidence in biotech companies.
- Strong Stock Performance: The stock surged 58% on its first trading day, closing above $31, reflecting investor enthusiasm for its innovative treatment technologies and potentially setting a solid foundation for future capital market performance.
- Significant R&D Progress: Parabilis's lead candidate, zolucatetide, is set to begin a phase 3 study for non-cancerous tumors in the first half of next year, having shown promising data in over 150 patients, suggesting potential breakthroughs in tumor treatment.
- Huge Market Potential: The Helicon platform allows for the targeting of previously
See More
Parabilis Achieves Record Biotech IPO with $670 Million Raise
- Record Financing: Parabilis Medicines raised $670 million in its IPO, surpassing Moderna's previous record of $604 million set in 2018, indicating strong investor interest and confidence in the biotech sector.
- Stock Surge: The company's stock soared 58% on its first trading day, closing at over $31, reflecting the market's enthusiastic response to its innovative cancer-fighting technology, potentially setting a solid foundation for future capital market performance.
- R&D Prospects: Parabilis's lead candidate, zolucatetide, is set to begin a phase 3 trial for non-cancerous tumors in the first half of next year, with over 150 patients studied so far showing
See More
Moderna's Future Looks Bright Despite Current Losses
- Product Line Expansion: Moderna currently has four commercial products, including two COVID-19 vaccines and an RSV vaccine, while developing over 30 vaccines and therapeutics; successful launches could significantly boost revenue.
- Cost Management Priority: The company has already trimmed hundreds of millions in expenses and anticipates an additional $500 million reduction next year by streamlining manufacturing and focusing on high-potential R&D projects, which could substantially lower losses.
- Strong Cash Position: Moderna holds $7.5 billion in cash, expecting a $2 billion loss this year, but with cost cuts and revenue from new products, future losses are projected to decrease significantly.
- Long-Term Financial Goals: Management has stated that Moderna aims to be cash flow positive by 2028, and if it can launch 10 commercial products while maintaining financial discipline, the future looks very promising.
See More
Moderna's Strategic Return and Future Outlook
- Manufacturing Capacity Gap: CEO Stéphane Bancel warns that continental Europe currently lacks mRNA manufacturing capacity, particularly after BioNTech's announcement to close its German facilities, emphasizing the importance of collaborating with the EU to establish local production to address potential pandemic risks.
- Product Line Diversification: Moderna is expanding its mRNA platform technology into cancer treatment, recently announcing a new therapy for Lynch syndrome aimed at enhancing cancer prevention in patients, while hoping this new product will boost the company's market performance.
- Sales Growth Outlook: Despite expectations of a significant drop in sales post-COVID-19, Bancel states that Moderna is set to return to a growth trajectory this year, with four infectious disease vaccines already approved by European regulators and more products in phase three trials expected to drive revenue recovery.
- Infrastructure Enhancement: With manufacturing facilities in the US, Canada, the UK, and Australia, Bancel asserts that these infrastructures will enable Moderna to respond more rapidly to future pandemics, significantly enhancing global preparedness.
See More
Moderna Shares Surpass Analyst Target Price of $46.62
- Stock Performance: Moderna Inc (Ticker: MRNA) recently traded at $49.70, surpassing the average analyst 12-month target price of $46.62, indicating strong market confidence in the company's future, potentially attracting more investor interest.
- Analyst Reactions: When a stock reaches its target price, analysts typically either downgrade their valuation or raise their target price; the current market response to Moderna may prompt analysts to reassess their targets to reflect improvements in the company's fundamentals.
- Target Price Distribution: Among the 21 analysts covered by Zacks, target prices range from $21.00 to $135.00, with a standard deviation of $22.579, highlighting varying market perspectives on Moderna's future performance, necessitating careful risk and opportunity assessment by investors.
- Investor Decision-Making: With MRNA's stock price exceeding the target price, investors are presented with a timely opportunity to reassess whether the current price is merely a short-term fluctuation or a precursor to even higher target prices, thus deciding whether to hold or reduce their positions.
See More
Parabilis Pharmaceuticals IPO Raises $670 Million, Stock Surges 58%
- Biotech Boom: In 2023, the biotech sector is thriving, with Parabilis Pharmaceuticals raising $670 million in its IPO, surpassing Moderna's previous record of $604 million, indicating strong investor interest in innovative cancer treatments.
- Stock Performance: Parabilis's stock surged 58% on its first trading day, closing above $31, reflecting positive market sentiment towards its unique drug development platform, potentially laying the groundwork for future commercialization.
- Rapid R&D Progress: The company's lead candidate, zolucatetide, is set to enter a phase 3 clinical trial for non-cancerous tumors in the first half of next year, with over 150 patients studied so far, showing promising initial data that could transform existing treatment options.
- Financial Challenges: Despite the successful IPO, Parabilis reported a loss of $145 million last year, with R&D expenses reaching $125 million, highlighting ongoing financial pressures that increase investment risks, particularly against the backdrop of high R&D costs in the biotech sector.
See More
Parabilis IPO Sets Record, Promising Biotech Prospects Ahead
- Record Fundraising: Parabilis raised $670 million in its IPO, surpassing Moderna's previous record of $604 million, indicating strong market interest and heightened investor confidence in biotech companies.
- Strong Stock Performance: The stock surged 58% on its first trading day, closing above $31, reflecting investor enthusiasm for its innovative treatment technologies and potentially setting a solid foundation for future capital market performance.
- Significant R&D Progress: Parabilis's lead candidate, zolucatetide, is set to begin a phase 3 study for non-cancerous tumors in the first half of next year, having shown promising data in over 150 patients, suggesting potential breakthroughs in tumor treatment.
- Huge Market Potential: The Helicon platform allows for the targeting of previously
See More
Parabilis Achieves Record Biotech IPO with $670 Million Raise
- Record Financing: Parabilis Medicines raised $670 million in its IPO, surpassing Moderna's previous record of $604 million set in 2018, indicating strong investor interest and confidence in the biotech sector.
- Stock Surge: The company's stock soared 58% on its first trading day, closing at over $31, reflecting the market's enthusiastic response to its innovative cancer-fighting technology, potentially setting a solid foundation for future capital market performance.
- R&D Prospects: Parabilis's lead candidate, zolucatetide, is set to begin a phase 3 trial for non-cancerous tumors in the first half of next year, with over 150 patients studied so far showing
See More
Moderna's Future Looks Bright Despite Current Losses
- Product Line Expansion: Moderna currently has four commercial products, including two COVID-19 vaccines and an RSV vaccine, while developing over 30 vaccines and therapeutics; successful launches could significantly boost revenue.
- Cost Management Priority: The company has already trimmed hundreds of millions in expenses and anticipates an additional $500 million reduction next year by streamlining manufacturing and focusing on high-potential R&D projects, which could substantially lower losses.
- Strong Cash Position: Moderna holds $7.5 billion in cash, expecting a $2 billion loss this year, but with cost cuts and revenue from new products, future losses are projected to decrease significantly.
- Long-Term Financial Goals: Management has stated that Moderna aims to be cash flow positive by 2028, and if it can launch 10 commercial products while maintaining financial discipline, the future looks very promising.
See More
